GenSpera CEO, Craig Dionne, to Present at BIO CEO & Investor Conference, February 10th

Business Wire

SAN ANTONIO, Texas--(BUSINESS WIRE)--

GenSpera, Inc. (GNSZ) announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO CEO & Investor Conference 2014, on Monday, February 10th, at 1:30 PM. The conference is taking place at the Waldorf Astoria Hotel in New York, NY.

Dr. Dionne will give an overview of GenSpera’s precisely targeted oncology drug platform as well as an update on the G-202 Phase II clinical program. The presentation will be available as a webcast one hour after the conclusion of the live event, and until May 11, 2014 at: http://www.veracast.com/webcasts/bio/ceoinvestor2014/73134179835.cfm.

About GenSpera

GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

Data from the G-202 Phase Ib program in solid tumor patients demonstrated that G-202 is well-tolerated with prolonged disease stabilization observed in several hepatocellular carcinoma (liver cancer) patients whose disease had previously worsened on standard therapy. A Phase II clinical trial in patients with hepatocellular carcinoma currently is underway.

For more information, please visit the Company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports filed with the Securities and Exchange Commission.

Contact:
GenSpera, Inc.
Craig Dionne, 210-479-8112
PhD, CEO
or
Media:
Planet Communications
Deanne Eagle, 917-837-5866
or
Investors:
BPC Financial Marketing
John Baldissera, 800-368-1217

Rates

View Comments (0)